Click here to close now.

SYS-CON MEDIA Authors: Liz McMillan, Carmen Gonzalez, Pat Romanski, Plutora Blog, Peter Silva

News Feed Item

Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results

SAN DIEGO, Feb. 28, 2014 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, today reported financial results for the three and twelve months ended December 31, 2013.

Recent highlights included:

  • Cadence entered into an agreement and plan of merger agreement with Mallinckrodt plc and one of its wholly owned indirect subsidiaries pursuant to which Mallinckrodt commenced a tender offer on February 19, 2014, to acquire all of the outstanding shares of Cadence common stock at a purchase price of $14.00 per share in cash.
  • Net product revenue for the fourth quarter of 2013 was $33.3 million, representing increases of $16.2 million, or 95%, from the fourth quarter of 2012, and $4.3 million, or 15%, from the third quarter of 2013.
  • License revenue of $2.0 million was recognized in the fourth quarter of 2013 from a one-time commercial milestone payment pursuant to the company's license agreement with Terumo Corporation.
  • Gross margin on sales of OFIRMEV was 65% for the fourth quarter of 2013, compared to 58%, for the fourth quarter of 2012.
  • Cash, cash equivalents and investments were $57.4 million as of December 31, 2013.

Financial Results
Cadence's net product revenue for the three months ended December 31, 2013, was $33.3 million, an increase of 95% from the $17.1 million in net product revenue recognized for the three months ended December 31, 2012. For the year ended December 31, 2013, Cadence's net product revenue was $110.5 million, an increase of 121% from the $50.1 million reported in 2012.

For the three months ended December 31, 2013, Cadence reported a net loss of $4.1 million, or $0.05 per share, compared to a net loss of $21.4 million, or $0.25 per share, for the comparable period in 2012. For the year ended December 31, 2013, Cadence reported a net loss of $24.3 million, or $0.28 per share, compared to a net loss of $81.0 million, or $0.95 per share, in 2012. Included in the company's net loss for the twelve months ended December 31, 2013, was a gain of $7.7 million recorded with respect to the waiver, termination and sale of Cadence's Incline assets in January 2013, for which the company received cash payments totaling $14.7 million. The company's net loss for the three and twelve months ended December 31, 2012, included impairment charges and a loss on the sale of equipment totaling $8.6 million pertaining to certain assets involved with the manufacture of OFIRMEV under the terminated development and supply agreement with Baxter Healthcare Corporation. Additionally, the Company recognized disposal costs of $0.3 million during the fourth quarter of 2012 for the inventory held while manufacturing was suspended at Baxter.

The company's gross margin on sales of OFIRMEV for the three months ended December 31, 2013, was 65%, compared to 58% for the same period in 2012. For the twelve months ended December 31, 2013, Cadence reported a gross margin of 66%, compared to 54% for 2012. These year-over-year increases were primarily the result of lower freight costs in 2013 and the impact of price increases implemented in 2012 and 2013. Operating expenses, including patent amortization, decreased $3.6 million, or 12%, for the three months ended December 31, 2013, to $26.8 million, from $30.3 million for the same period in 2012. This decrease was primarily attributable to impairment charges and a loss on the sale of equipment totaling $8.6 million pertaining to certain assets involved with the manufacture of OFIRMEV under the terminated development and supply agreement with Baxter that were recognized during the three months ended December 31, 2012. Similar charges were not recorded in 2013, however the company incurred higher legal and clinical trial expenses during the three-months ended December 31, 2013 as compared to the same period in 2012. For the twelve months ended December 31, 2013, Cadence reported operating expenses of $102.1 million, a decrease of $1.5 million, or 1%, as compared to $103.6 million for 2012. This decrease was primarily attributable to the impairment charge and loss on equipment sale recorded during the fourth quarter of 2012, mostly offset by higher legal expenses, clinical trial expenses and corporate development activities in 2013 as compared to 2012.

As of December 31, 2013, Cadence held cash, cash equivalents and short-term investments of $57.4 million, a decrease of $4.7 million from $62.1 million at December 31, 2012. Net accounts receivable at December 31, 2013, was $9.3 million, representing approximately 30 days of sales outstanding.

About OFIRMEV® (Acetaminophen) Injection
OFIRMEV (acetaminophen) injection (1000 mg / 100 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The FDA approval of OFIRMEV was based on data from clinical trials in approximately 1,020 adult and 355 pediatric patients. These trials included two studies evaluating the safety and effectiveness of OFIRMEV in the treatment of pain, and one study evaluating OFIRMEV in the treatment of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.

Important Safety Information

RISK OF MEDICATION ERRORS AND HEPATOTOXICITY
Take care when prescribing, preparing, and administering OFIRMEV injection to avoid dosing errors which could result in accidental overdose and death.


OFIRMEV contains acetaminophen. Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed the recommended maximum daily limits, and often involve more than one acetaminophen-containing product.

OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation.  Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. Rarely, acetaminophen may cause serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal.  Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur, or at the first appearance of skin rash. Do not use in patients with acetaminophen allergy.

The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated with postsurgical pain. OFIRMEV is approved for use in patients ≥ 2 years of age. Do not exceed the recommended maximum daily dose of OFIRMEV. OFIRMEV should be administered only as a 15-minute infusion.

For more information, please see the full OFIRMEV Prescribing Information, including the complete boxed warning, which is available at www.OFIRMEV.com or www.cadencepharm.com.

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the Investors page of www.cadencepharm.com under "Events & Presentations" by selecting "Corporate Overview."

Forward-Looking Statements
Statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Such statements include, without limitation, statements regarding the pending acquisition of Cadence by Mallinckrodt plc. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Cadence's actual future results may differ materially from Cadence's current expectations due to the risks and uncertainties inherent in its business. These risks include, but are not limited to: uncertainties as to the timing of the pending Mallinckrodt acquisition; uncertainties as to the percentage of Cadence stockholders tendering their shares in the tender offer; the possibility that competing offers will be made; the possibility that various closing conditions for the Mallinckrodt acquisition may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the effects of disruption caused by the Mallinckrodt acquisition making it more difficult to maintain relationships with employees, collaborators, vendors and other business partners; the risk that stockholder litigation in connection with the Mallinckrodt acquisition may result in significant costs of defense, indemnification and liability; Cadence's dependence on the successful commercialization of OFIRMEV, which is the company's only product; Cadence's ability to achieve broad market acceptance and generate revenues from sales of OFIRMEV; Cadence's dependence on its contract manufacturers and its ability to ensure an adequate and continued supply of OFIRMEV to meet market demand; Cadence's ability to successfully enforce its marketing exclusivities and intellectual property rights, and to defend the patents covering OFIRMEV, including in current intellectual property litigation with the parties that have submitted new drug applications ("NDAs") or abbreviated new drug applications ("ANDAs") for generic versions of OFIRMEV; the potential that Cadence may be required to continue intellectual property litigation for substantial lengths of time or file additional lawsuits to defend its patent rights from challenges by companies that have submitted NDAs or ANDAs for generic versions of OFIRMEV, and the substantial costs associated with such lawsuits; the potential for the U.S. patent and trademark office to grant the reexamination of U.S. patent no. 6,992,218 (the "'218 patent"), which is related to OFIRMEV, and the potential that any claims in the '218 patent or in U.S. patent no. 6,028,222, which also relates to OFIRMEV and is currently undergoing reexamination, are invalidated or narrowed in scope; the potential introduction of generic competition to OFIRMEV in the event Cadence is unsuccessful in defending the patents covering OFIRMEV or in current or future intellectual property litigation, and the impact it may have on the sales and pricing of the product; Cadence's dependence on its licensors for the maintenance and enforcement of its intellectual property rights; the potential product liability exposure associated with pharmaceutical products such as OFIRMEV and other products Cadence may in-license or acquire; Cadence's ability to fully comply with numerous federal, state and local laws and regulatory requirements that apply to its commercial activities; public concern regarding the safety of drug products such as OFIRMEV, and the potential implementation by regulatory agencies of new requirements to include unfavorable information in the labeling for OFIRMEV; the risk that Cadence may not be able to raise sufficient capital when needed, or at all; and other risks detailed under "Risk Factors" and elsewhere in Cadence's periodic reports and other filings made with the Securities and Exchange Commission from time to time. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995, and Cadence undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Cadence® and OFIRMEV® are trademarks of Cadence Pharmaceuticals, Inc.

Contact:

William R. LaRue


SVP & Chief Financial Officer


Cadence Pharmaceuticals, Inc.


Phone: 858-436-1400

                                                

CADENCE PHARMACEUTICALS, INC.

CONDENSED STATEMENTS OF OPERATIONS

(unaudited)

(in thousands, except per share amounts)








Three Months Ended


Twelve Months Ended



December 31,


December 31,



2013


2012


2013


2012

Revenues:









Product revenue, net

$ 33,286


$  17,089


$ 110,529


$  50,066


License revenue

2,027


85


2,027


118

        Total revenues

35,313


17,174


112,556


50,184



















Costs and expenses:









Cost of product sales

11,548


7,178


37,973


23,256


Amortization of patent license

335


335


1,343


1,343


Research and development

2,045


1,073


6,743


6,519


Selling, general and administrative

24,221


20,032


94,482


86,843


Impairment of long-lived assets

-


7,723


-


7,723


Other

161


1,160


(441)


1,174

        Total costs and expenses

38,310


37,501


140,100


126,858










Loss from operations

(2,997)


(20,327)


(27,544)


(76,674)










Other (expense) income, net

(1,121)


(1,094)


3,250


(4,299)










Net loss

$ (4,118)


$ (21,421)


$ (24,294)


$ (80,973)










Basic and diluted net loss per share

$   (0.05)


$     (0.25)


$     (0.28)


$     (0.95)










Shares used to compute basic and








diluted net loss per share

86,344


85,591


85,969


85,556

 

CADENCE PHARMACEUTICALS, INC.

CONDENSED BALANCE SHEETS

(in thousands)






December 31,


December 31,


2013


2012


(unaudited)



Assets




Current assets:




    Cash, cash equivalents and short-term investments 

$            57,401


$            62,072

    Restricted cash 

548


640

    Accounts receivable, net 

9,300


6,152

    Inventory 

8,646


6,498

    Prepaid expenses and other current assets 

1,993


1,154

        Total current assets

77,888


76,516





Property and equipment, net

2,060


1,967

Intangible assets, net

10,747


12,090

Other assets

108


7,106

        Total assets

$            90,803


$            97,679





Liabilities and Stockholders' Equity 




Current liabilities:




    Accounts payable 

$              7,724


$              5,796

    Accrued liabilities 

18,042


12,969

    Deferred revenue 

-


2,234

    Current portion of long-term debt, less discount 

10,777


-

        Total current liabilities

36,543


20,999





Other liabilities

844


51

Long-term debt, less discount

18,538


28,818

Total stockholders' equity

34,878


47,811

        Total liabilities and stockholders' equity

$            90,803


$            97,679

SOURCE Cadence Pharmaceuticals, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Docker is becoming very popular--we are seeing every major private and public cloud vendor racing to adopt it. It promises portability and interoperability, and is quickly becoming the currency of the Cloud. In his session at DevOps Summit, Bart Copeland, CEO of ActiveState, discussed why Docker is so important to the future of the cloud, but will also take a step back and show that Docker is actually only one piece of the puzzle. Copeland will outline the bigger picture of where Docker fits a...
Since 2008 and for the first time in history, more than half of humans live in urban areas, urging cities to become “smart.” Today, cities can leverage the wide availability of smartphones combined with new technologies such as Beacons or NFC to connect their urban furniture and environment to create citizen-first services that improve transportation, way-finding and information delivery. In her session at @ThingsExpo, Laetitia Gazel-Anthoine, CEO of Connecthings, will focus on successful use c...
The Workspace-as-a-Service (WaaS) market will grow to $6.4B by 2018. In his session at 16th Cloud Expo, Seth Bostock, CEO of IndependenceIT, will begin by walking the audience through the evolution of Workspace as-a-Service, where it is now vs. where it going. To look beyond the desktop we must understand exactly what WaaS is, who the users are, and where it is going in the future. IT departments, ISVs and service providers must look to workflow and automation capabilities to adapt to growing ...
Software Defined Storage provides many benefits for customers including agility, flexibility, faster adoption of new technology and cost effectiveness. However, for IT organizations it can be challenging and complex to build your Enterprise Grade Storage from software. In his session at Cloud Expo, Paul Turner, CMO at Cloudian, looked at the new Original Design Manufacturer (ODM) market and how it is changing the storage world. Now Software Defined Storage companies can build Enterprise grade ...
Sensor-enabled things are becoming more commonplace, precursors to a larger and more complex framework that most consider the ultimate promise of the IoT: things connecting, interacting, sharing, storing, and over time perhaps learning and predicting based on habits, behaviors, location, preferences, purchases and more. In his session at @ThingsExpo, Tom Wesselman, Director of Communications Ecosystem Architecture at Plantronics, will examine the still nascent IoT as it is coalescing, includin...
Almost everyone sees the potential of Internet of Things but how can businesses truly unlock that potential. The key will be in the ability to discover business insight in the midst of an ocean of Big Data generated from billions of embedded devices via Systems of Discover. Businesses will also need to ensure that they can sustain that insight by leveraging the cloud for global reach, scale and elasticity.
The Internet of Things (IoT) promises to evolve the way the world does business; however, understanding how to apply it to your company can be a mystery. Most people struggle with understanding the potential business uses or tend to get caught up in the technology, resulting in solutions that fail to meet even minimum business goals. In his session at @ThingsExpo, Jesse Shiah, CEO / President / Co-Founder of AgilePoint Inc., showed what is needed to leverage the IoT to transform your business. ...
Hadoop as a Service (as offered by handful of niche vendors now) is a cloud computing solution that makes medium and large-scale data processing accessible, easy, fast and inexpensive. In his session at Big Data Expo, Kumar Ramamurthy, Vice President and Chief Technologist, EIM & Big Data, at Virtusa, will discuss how this is achieved by eliminating the operational challenges of running Hadoop, so one can focus on business growth. The fragmented Hadoop distribution world and various PaaS soluti...
IoT is still a vague buzzword for many people. In his session at @ThingsExpo, Mike Kavis, Vice President & Principal Cloud Architect at Cloud Technology Partners, discussed the business value of IoT that goes far beyond the general public's perception that IoT is all about wearables and home consumer services. He also discussed how IoT is perceived by investors and how venture capitalist access this space. Other topics discussed were barriers to success, what is new, what is old, and what th...
The true value of the Internet of Things (IoT) lies not just in the data, but through the services that protect the data, perform the analysis and present findings in a usable way. With many IoT elements rooted in traditional IT components, Big Data and IoT isn’t just a play for enterprise. In fact, the IoT presents SMBs with the prospect of launching entirely new activities and exploring innovative areas. CompTIA research identifies several areas where IoT is expected to have the greatest impac...
The Internet of Things (IoT) is rapidly in the process of breaking from its heretofore relatively obscure enterprise applications (such as plant floor control and supply chain management) and going mainstream into the consumer space. More and more creative folks are interconnecting everyday products such as household items, mobile devices, appliances and cars, and unleashing new and imaginative scenarios. We are seeing a lot of excitement around applications in home automation, personal fitness,...
Advanced Persistent Threats (APTs) are increasing at an unprecedented rate. The threat landscape of today is drastically different than just a few years ago. Attacks are much more organized and sophisticated. They are harder to detect and even harder to anticipate. In the foreseeable future it's going to get a whole lot harder. Everything you know today will change. Keeping up with this changing landscape is already a daunting task. Your organization needs to use the latest tools, methods and ex...
In his session at DevOps Summit, Tapabrata Pal, Director of Enterprise Architecture at Capital One, will tell a story about how Capital One has embraced Agile and DevOps Security practices across the Enterprise – driven by Enterprise Architecture; bringing in Development, Operations and Information Security organizations together. Capital Ones DevOpsSec practice is based upon three "pillars" – Shift-Left, Automate Everything, Dashboard Everything. Within about three years, from 100% waterfall, C...
Disruptive macro trends in technology are impacting and dramatically changing the "art of the possible" relative to supply chain management practices through the innovative use of IoT, cloud, machine learning and Big Data to enable connected ecosystems of engagement. Enterprise informatics can now move beyond point solutions that merely monitor the past and implement integrated enterprise fabrics that enable end-to-end supply chain visibility to improve customer service delivery and optimize sup...
Dale Kim is the Director of Industry Solutions at MapR. His background includes a variety of technical and management roles at information technology companies. While his experience includes work with relational databases, much of his career pertains to non-relational data in the areas of search, content management, and NoSQL, and includes senior roles in technical marketing, sales engineering, and support engineering. Dale holds an MBA from Santa Clara University, and a BA in Computer Science f...